外皮拉米德式高动力运动障碍的症状治疗
Gregory de Boer1,2, Robertus Maria Alfonsius de Bie1, Bart Erik Kris Sylvain Swinnen1
1Department of Neurology and Clinical Neurophysiology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
Current neuropharmacology
|June 7, 2024
概括
治疗高动力运动障碍,如胆, dystonia,和是复杂的. 本综述涵盖当前和未来的疗法,重点关注实际管理和不利影响,以改善患者护理.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 外皮拉米德性高动力运动障碍表现出多种症状,如胆发病, dystonia 和 tics.
- 目前的治疗方法面临挑战,因为症状重叠,有效性数据有限,安全性问题.
研究的目的:
- 提供对外皮拉米德高动力运动障碍的当前治疗方法的全面审查.
- 为指导治疗选择提供实用概述,包括机制,剂量和不良影响管理.
主要方法:
- 对各种治疗方案的现有证据的审查.
- 讨论深度大脑刺激和优化多巴胺降低剂.
- 分析治疗的复杂性,包括剂量和副作用管理.
主要成果:
- 治疗场景复杂,受到深度大脑刺激和先进药理学剂的影响.
- 详细检查不同疗法的作用机制.
- 专注于剂量和管理不良影响的实际方面.
结论:
- 高动力运动障碍的有效管理需要个性化的治疗策略.
- 该评论通过详细介绍当前的证据和实际考虑,帮助临床医生选择合适的治疗方法.
- 未来的治疗发展也被强调为正在进行的研究和临床应用.
相关概念视频
Parkinson's Disease: Treatment
257
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
257
Parkinson's Disease: Overview
527
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
527
Antipsychotic Drugs: Therapeutic Uses and Side Effects
168
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
168
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
307
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
307
Psychosis: Goals of Pharmacotherapy
123
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
123


